RESEARCH STUDIES & CLINICAL TRIALS

With over 600 published studies, we can let the science speak for itself

icon of the outline of a microscope

INDEPENDENT RESEARCH

We encourage a broad range of scientific research. Over $60 million has been invested in independent studies exploring the advanced benefits of MitoQ.

GLOBAL RECOGNITION

Leading institutions around the world have studied MitoQ’s cellular health optimization in over 600 peer-reviewed scientific papers and 14 clinical trials to date.

CONTINUED INNOVATION

Our product development team continues to explore the leading edge of cellular health science, resulting in over 60 global patents for our molecular technology.

Highlighted studies

HEART

Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults

Rossman MJ et al. Hypertension. 2018;71:1056-1063.

DOI: DOI: 10.1161/HYPERTENSIONAHA.117.10787 source

MitoQ decreases free radical production by mitochondria, and significantly supports arterial function in older adults and therefore the health of the arteries. In the clinical trial it was validated that: MitoQ greatly improved the ability of arteries to dilate (by 42%), MitoQ significantly supports the health of aorta & MitoQ significantly fights oxidative Stress.

Read the summary

EXERCISE

Mitochondria-Targeted Antioxidant Supplementation Improves 8km Time Trial Performance in Middle-Aged Trained Male Cyclist

Broome SC et al. Journal of the International Society of Sports Nutrition. 18, 58 (2021).

DOI: DOI: 10.1186/s12970-021-00454-0 source

The study showed that after 4 weeks of MitoQ supplementation, the mean completion time for a time trial was 1.3% faster and an increase of 10 watts of power. MitoQ supplementation may be an effective nutritional strategy to attenuate exercise-induced increases in oxidative damage to lipids and improve cycling performance.

Read the summary

SAFETY

The influence of acute high dose MitoQ on urinary kidney injury markers in healthy adults

Linder BA et al. The FASEB Journal (volume 36, issue S1).

DOI: DOI: 10.1096/fasebj.2022.36.S1.L7715 source

Results found that acute, high-dose MitoQ supplementation did not result in high concentrations of kidney injury biomarkers compared to placebo samples. Preliminary evidence is that ongoing MitoQ use in the normal range (10mg-20mg) is beneficial to kidney health.

Read the summary
MitoQ

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. MitoQ supplement testimonials may not be typical and individual results may vary.